Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Gastric cancer is one of the most common malignant tumors in China, and the incidence and
mortality rate are second in malignant tumors. The treatment of gastric cancer need
integrated multidisciplinary treatment, and surgery is the only possible curative method for
gastric cancer at present. Previous studies have reported that neoadjuvant chemoradiotherapy
can downstage primary tumor to increase radical resection rate in order to improve the
long-term prognosis of advanced gastric cancer. However, there is no study on the application
of hypo-radiotherapy to neoadjuvant radiotherapy in gastric cancer. The aim of this study was
to observe the maximum tolerated dose (MTD) and dose limited toxicity (DLT) of
hypo-fractionated radiotherapy for locally advanced gastric cancer.